Showing 8161-8170 of 8647 results for "".
- New Software Update Expands Capabilities of the OD-OS Navilas 577shttps://modernod.com/news/new-software-update-expands-capabilities-of-the-od-os-navilas-577s/2476754/OD-OS has released a new software update for its Navilas 577s. With a new multimodal “export wizard,” retina specialists can generate high resolution images of their treatments in different configurations. This allows for advanced, transparent documentation for all purposes and record
- Eye Specialist Works to Prevent Motor Vehicle Related Traumatic Eye Injurieshttps://modernod.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/Within a 6-week period, Grady Memorial Hospital eye specialist Yousuf Khalifa, MD, witnessed an unusual set of traumatic eye injuries. Three patients, all riding with their windows down, suffered serious eye injuries when the glass in their exterior rear-facing side
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging-2/2476749/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a Medscape
- EKF Quo-Test Supports Improved Medical Management of Diabetic Retinopathy Patientshttps://modernod.com/news/ekf-quo-test-supports-improved-medical-management-of-diabetic-retinopathy-patients/2476736/EKF Diagnostics announced that its Quo-Test HbA1c analyzer is supporting improved medical management of patients with sight-threatening diabetic retinopathy (DR). The effectiveness of this point-of-care HbA1c testing application for rapid assessment of glycaemic control in eye clinic patients has
- US Scraps Proposal to Curb Drug Rebates Paid to Pharmacy Benefit Managershttps://modernod.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/The US government pulled the plug on plans designed to reduce drug prices by limiting rebates paid by drugmakers to pharmacy benefit managers (PBMs). White House spokesman Judd Deere said on Thursday that “based on careful analysis and thorough consideration, the President has decided to wi
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly
- Double-Barreled Biologic for Diabetic Retinopathy Emerginghttps://modernod.com/news/double-barreled-biologic-for-diabetic-retinopathy-emerging/2476720/Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF), the only pathway for which there are approved therapies, and are developing treatments that can be administered less often, according to a
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Wize Pharma Enters Joint Venture With Cannabics Pharmaceuticals to Develop Cannabinoid Ophthalmic Treatmentshttps://modernod.com/news/wize-pharma-enters-joint-venture-with-cannabics-pharmaceuticals-to-develop-cannabinoid-ophthalmic-treatments/2476713/Israel-based Wize Pharma and Cannabics Pharmaceuticals have together created and adopted a business plan for a joint venture focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the joint venture was a con